现货,AZD6244 (Selumetinib), CAS号:606143-52-6,美国进口,MAPK , MEK , MEK 抑制剂和化合物,selleck,目录号S1008

信号转导通路:  MAPK >> MEK >> MEK 抑制剂和化合物 >> 

技术数据:

分子量(MW): 457.68 AZD6244 (Selumetinib) Chemical Structure
化学式:

C17H15BrClFN4O3

溶解度: DMSO ≥92mg/mL   Water <1mg/mL   Ethanol <1mg/mL
纯度: >99%
稳定性: at -20℃ 2 years
CAS号: 606143-52-6

生物活性

 

AZD6244非常有效地抑制MEK1,IC50为14nM。AZD6244是ATP非竞争性的抑制剂,在IC50浓度小于40 nM时使ERK1/2的磷酸化作用失活。AZD6244也通过抑制ERK1/2和p90RSK的磷酸化抑制原代HCC细胞的生长,同时伴随着caspase-3和caspase-7分裂的加强, 及断裂的聚腺苷二磷酸核糖聚合酶的增多。[1] AZD6244对感知乳腺癌细胞系中的raf突变和非小细胞肺癌细胞系中的ras突变很灵敏[2]。AZD6244在P38,JNK,PI3K,及MEK5/ERK5通路中的作用不大。活体研究显示AZD6244在2-1318, 5-1318, 及26-1004 4-1318移植物中明显抑制ERK1/2的磷酸化,并且在原代2-1318细胞中通过激活caspase通路诱导细胞凋亡。[1] HT-29 移植瘤是携带B-raf突变的直肠瘤模型,AZD6244 在100mg/kg剂量时可以抑制HT-29移植瘤中肿瘤的增长,并且 AZD6244作用下的肿瘤指数比吉西他滨作用下的肿瘤指数要好。[3] 另外,AZD6244可以抑制HCC移植瘤的增长,HCC移植瘤的增长与细胞凋亡的增多,及细胞周期调控的减量调节有关。包括:cyclin D1, cdc-2, CDK 2 ,CDK4, cyclin B1, 及 c-Myc。 [4] AZD6244可以用于治疗多种癌症,包括直肠癌,非小细胞肺癌,胰腺癌,乳腺癌等。AZD6244用于治疗非小细胞肺癌目前还处在二期临床试验阶段。AZD6244最初是由Array BioPharma研究的,目前由Astra Zeneca在研究。

 

客户反馈数据

AZD6244 (Selumetinib) Review INA-6 MM cells were treated with AS703026 or AZD6244 for 2 d, followed by [3H]thymidine uptake assay. PBMCs isolated from normal donors (n = 3) were incubated with M-CSF and RANKL, in the presence or absence of AS703026 or AZD6244 for 14 d. The TRAP assay was performed to measure the formation of multinuclear osteoclast cells (OC).
AZD6244 (Selumetinib) Review

AZD6244 enhanced FOXO3a expression and induced suppression of cancer cell proliferation. A, tumor volume of the HCT116 xenografts treated with Placebo or AZD6244 was measured for 21 d. The tumor sections of four individual DMSO or AZD6244-treated HCT116 xenografts were subjected to immunohistochemistry with a FOXO3a antibody. Relative percentages of nuclear FOXO3a expression of individual xenograft tumors from B were analyzed and the mean values of FOXO3a expression in Placebo or AZD6244-treated group were indicated as bars.

AZD6244 (Selumetinib) Review

lysates from various cancer cell lines: breast cancer (MDA-MB-435), colon cancer (HCT116, SW620, and HT29), and melanoma (WM793) treated with DMSO or AZD6244 (10 μmol/L) for 4 h were subjected to immunoblotting with the indicated antibodies.

 

 

AZD6244 (Selumetinib) Review

B-RafV600E mutated melanoma line,A375, was treated with different doses of AZD6244 for 1hour or 24 hours.Cell lysates were analyzed by Western Blotting to determine the levels of phosphorylated ERK1/2(Perk1/2)

 

 

AZD6244 (Selumetinib) Review

A,ERK phosphorylation in A375 expressing indicated ORFs following treatment with DMSO or 1 mM of PLX4720, RAF265, CI-1040 or AZD6244. B,ERK phosphorylation in A375 expressing indicated ORFs following treatment with DMSO, PLX4720 (1 mM) or PLX4720 in combination with CI-1040 or AZD6244 (all 1 mM).

AZD6244 (Selumetinib) Review

Ex vivo and functional characterization of MEK1(P124L). (A) AZD6244-mediated growth inhibition ex vivo of treatment-naïve BRAFV600E melanoma cells (black and blue) or cells cultured from an AZD6244-resistant metastatic focus (red). (B) ERK phosphorylation (p-ERK) andMEKphosphorylation (p-MEK) are shown following treatment with increasing concentrations of AZD6244 in treatment-naïve or AZD6244-resistant melanoma cells cultured ex vivo. The tubulin loading control (-tubulin) is also shown. (C) AZD6244 growth inhibition curves of parental A375 (solid black), A375 cells expressing MEK-DD (grey), wild-type MEK1 (hatched black), or MEK1(P124L) (red) are shown. In each instance n6 anderrorstandard deviation. (D) p-ERK and p-MEK are shown following treatment with increasing AZD6244 concentrations in the cell lines described in C, Above. The -tubulin control is also shown.

 

 

AZD6244 (Selumetinib) Review

A and B, clonogenic assays in 2 melanoma cell lines (YUVON and YUSIK) treated with NVPBEZ235 (BEZ) and AZD6244 (AZD) alone and in combination. Combinations were more effective in inhibiting colony formation at lower concentrations than either drug alone.

AZD6244 (Selumetinib) Review

Survival curves for isogenic cell line pairs and melanoma cultures treated with the indicated AZD6244 concentration for 72 h (relative to DMSO treated controls; mean6s.e.m., n55). PLX4032 resistant cells were grown with PLX4032. Dashed line, 50% cell killing.

退换货政策        
 1、 退换货只针对已付款用户。一张订单Selleck只提供一次退换货服务,为了确保您的权益,请考虑周全后与我们联系。         2、请您确保退换货时,商品、配件、赠品及各种包装完整。         3、因您个人原因造成的商品损坏(如自行使用、分装、受潮、变质、非原物品的等)将不予退换。           4、Selleck目前只支持商品一换一服务,换货时无法加定商品。         5、如您购买商品时Selleck上海办事处已向您提供发票,则办理退货或订单金额发生变更的换货时,请将发票随商品一同返还给Selleck上海办事处赛导通生物科技(上海)有限公司,请您妥善保管发票,如发票丢失,将无法办理退换货。         6、您的订单若办理退换货,运费金额会在您的实际退款中扣除。

Write a comment

Comments: 0



赛导通生物科技联系方式:


上海市黄浦区江西中路261号509室,

近南京东路外滩


电话 400-168-1698


传真 021 3326 0586


邮箱: info@selleck.cn 

 技术: tech@selleck.cn



Selleck癌症肿瘤研究周刊


Stu.la 司途拉生物
Stu.la 司途拉生物